Infosys, Wipro decline despite upbeat Q2 earnings; margin concerns weigh
Ionis Pharmaceuticals (NASDAQ:IONS), a $9.5 billion biotech company, saw its Executive Vice President of Research Eric Swayze sell 11,130 shares of company stock on September 2, 2025, for approximately $552,861. The sales were executed in two transactions with prices ranging from $49.22 to $53.6829. The stock has shown remarkable strength recently, gaining 39% in the past week alone, with InvestingPro data indicating overbought conditions.
The first sale involved 10,000 shares sold at a weighted average price of $49.22, with individual sales prices ranging from $49.14 to $49.54. The total value of this transaction was $492,200. The second sale consisted of 1,130 shares at a weighted average price of $53.6829, with prices ranging from $53.64 to $53.72, for a total value of $60,661. The stock currently trades near $59.35, approaching its 52-week high of $62.08.
Following these transactions, Swayze directly owns 37,302 shares of Ionis Pharmaceuticals. Additionally, he indirectly owns 184 shares through his son. The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2024. Want deeper insights? InvestingPro subscribers have access to 12 additional exclusive tips and comprehensive analysis for IONS, including detailed valuation metrics and financial health scores.
In other recent news, Ionis Pharmaceuticals has reported positive results from its Phase 3 CORE and CORE2 trials for its triglyceride-lowering drug, leading to significant attention from analysts and investors. The trials showed statistically significant benefits, including a reduction in triglyceride levels and a decrease in acute pancreatitis risk, which Bernstein SocGen Group described as exceeding high expectations. Following these results, H.C. Wainwright raised its price target for Ionis Pharmaceuticals to $95, citing strong triglyceride reductions in the studies. Oppenheimer also increased its price target to $81, maintaining an Outperform rating due to the promising trial outcomes for Tryngolza (olezarsen).
Additionally, RBC Capital adjusted its price target to $80, highlighting the potential of Ionis’s acute pancreatitis treatment based on positive Phase III data. BMO Capital upgraded Ionis Pharmaceuticals from Market Perform to Outperform, expressing confidence in the blockbuster potential of Olezarsen, which surpassed expectations in its performance. These developments reflect growing optimism about Ionis Pharmaceuticals’ drug pipeline and its potential impact on the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.